Anavex Life SciencesAVXL +6.50%31 Pretax Margin % is % as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Anavex Life Sciences ranks worse than 105708.14% on this metric.
The historical rank and industry rank for Anavex Life Sciences's Pretax Margin % or its related term are showing as below:
AVXL's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5 * Ranked among companies with meaningful Pretax Margin % only.
Anavex Life Sciences (NAS:AVXL) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Anavex Life Sciences Pretax Margin % Related Terms
Anavex Life Sciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVXL vs ZNTL, HUMA, SABS: Pretax Margin % Comparison
For the Biotechnology subindustry, Anavex Life Sciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (AVXL) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #999999 out of 946 companies in the Biotechnology industry.
Is Anavex Life Sciences' Pretax Margin % too high?
Anavex Life Sciences' current Pretax Margin % is %. Based on the distribution chart, Anavex Life Sciences ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anavex Life Sciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Pretax Margin % compare to ZNTL and HUMA?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #999999 out of 946 companies for Pretax Margin %. This places Anavex Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Pretax Margin % of %. The current Pretax Margin % is %. Anavex Life Sciences' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
31GF Score
Get the complete analysis for AVXL
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
